Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter,placebo-controlled,double-blind,randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin |
| |
Authors: | Hideaki Yahata Hiroaki Kobayashi Kenzo Sonoda Mototsugu Shimokawa Tatsuhiro Ohgami Toshiaki Saito Shinji Ogawa Kunihiro Sakai Akimasa Ichinoe Yousuke Ueoka Yasuyuki Hasuo Makoto Nishida Satohiro Masuda Kiyoko Kato |
| |
Affiliation: | 1.Department of Obstetrics and Gynecology,Kyushu University Hospital,Fukuoka,Japan;2.Department of Obstetrics and Gynecology, Faculty of Medicine,Kagoshima University Hospital,Kagoshima,Japan;3.Center of Clinical Research, National Kyushu Cancer Center,Fukuoka,Japan;4.Department of Obstetrics and Gynecology,Miyazaki Prefectural Hospital,Miyazaki,Japan;5.Gynecology Service,National Kyushu Cancer Center,Fukuoka,Japan;6.Department of Obstetrics and Gynecology,Kyushu Hospital,Kitakyushu,Japan;7.Department of Obstetrics and Gynecology,Saiseikai Fukuoka Hospital,Fukuoka,Japan;8.Department of Obstetrics and Gynecology,Kitakyushu Municipal Medical Center,Kitakyushu,Japan;9.Department of Obstetrics and Gynecology,Hamanomachi Hospital,Fukuoka,Japan;10.Department of Obstetrics and Gynecology,National Kyushu Medical Center,Fukuoka,Japan;11.Department of Obstetrics and Gynecology,Fukuoka Red Cross Hospital,Fukuoka,Japan;12.Department of Pharmacy,Kyushu University Hospital,Fukuoka,Japan |
| |
Abstract: | BackgroundSubstance P contributes to the hypersensitivity reaction (HSR) to paclitaxel in a rat model. Aprepitant acts as an inhibitor of the binding of substance P to the neurokinin-1 receptor and, consequently, may reduce the frequency of paclitaxel-induced HSR. While aprepitant has a prophylactic effect against vomiting caused by high-dose cisplatin, the benefits of aprepitant have not been clearly demonstrated in patients receiving paclitaxel and carboplatin (TC) combination chemotherapy.MethodsWe conducted a multicenter, placebo-controlled, double-blind, randomized study in Japanese patients with gynecologic cancer who received TC combination chemotherapy. Patients received aprepitant or placebo together with both a 5-HT3 receptor antagonist and dexamethasone prior to chemotherapy. The primary endpoint was the proportion of patients with HSR, and the secondary endpoints were the proportion of patients with “no vomiting”, “no significant nausea”, and complete response, respectively.ResultsOf the 324 randomized patients, 297 (151 in the aprepitant group; 146 in the placebo group) were evaluated. The percentage of patients with HSR (9.2 vs. 7.5 %, respectively; P = 0.339) was not significantly different between the groups. The percentage of “no vomiting” patients (78.2 vs. 54.8 %; P < 0.0001), “no significant nausea” patients (85.4 vs. 74.7 %; P = 0.014), and patients showing complete response (61.6 vs. 47.3 %, P = 0.0073) was significantly higher in the aprepitant group than in the placebo group.ConclusionThe administration of aprepitant did not have a prophylactic effect on the HSR but was effective in reducing nausea and vomiting in gynecologic cancer patients receiving TC combination chemotherapy. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|